| Year |
Citation |
Score |
| 2024 |
Passos Barbosa MM, Kamerer RL, Schmit J, Lopez AJ, Uyehara R, Tighe R, Battula S, Kaufman HL, Fan TM. Preclinical evaluation of an anchored immunotherapy strategy with aluminum hydroxide-tethered interleukin-12 in dogs with advanced malignant melanoma. Molecular Cancer Therapeutics. PMID 39632727 DOI: 10.1158/1535-7163.MCT-24-0317 |
0.301 |
|
| 2024 |
Mooradian MJ, Fintelmann FJ, LaSalle TJ, Simon J, Graur A, Muzikansky A, Mino-Kenudson M, Shalhout S, Kaufman HL, Jenkins RW, Lawrence D, Lawless A, Sharova T, Uppot RN, Fang J, et al. Cryoablation and post-progression immune checkpoint inhibition in metastatic melanoma: a phase II trial. Nature Communications. 15: 7357. PMID 39191779 DOI: 10.1038/s41467-024-51722-x |
0.314 |
|
| 2024 |
Bommareddy PK, Wakimoto H, Martuza RL, Kaufman HL, Rabkin SD, Saha D. Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival. Journal For Immunotherapy of Cancer. 12. PMID 38599661 DOI: 10.1136/jitc-2024-008880 |
0.309 |
|
| 2019 |
Silk AW, Kaufman HL, Curti B, Mehnert JM, Margolin K, McDermott D, Clark J, Newman J, Bommareddy PK, Denzin L, Najmi S, Haider A, Shih W, Kane MP, Zloza A. High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma. Frontiers in Oncology. 9: 1483. PMID 31998643 DOI: 10.3389/Fonc.2019.01483 |
0.319 |
|
| 2019 |
Fishman M, Dutcher JP, Clark JI, Alva A, Miletello GP, Curti B, Agarwal N, Hauke R, Mahoney KM, Moon H, Treisman J, Tykodi SS, Daniels G, Morse MA, Wong MKK, ... Kaufman H, et al. Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM registry. Journal For Immunotherapy of Cancer. 7: 84. PMID 30917871 DOI: 10.1186/S40425-019-0567-3 |
0.393 |
|
| 2019 |
Middleton MR, Sacco JJ, Merchan JR, Curti BD, Vanderwalde AM, Olsson-Brown AC, Aroldi F, Fotiadis N, Baum S, Coffin RS, Kaufman H, Harrington KJ. An open label, multicenter, phase I/II study of RP1 as a single agent and in combination with PD1 blockade in patients with solid tumors. Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.Tps2671 |
0.311 |
|
| 2018 |
D'Angelo SP, Russell J, Lebbé C, Chmielowski B, Gambichler T, Grob JJ, Kiecker F, Rabinowits G, Terheyden P, Zwiener I, Bajars M, Hennessy M, Kaufman HL. Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial. Jama Oncology. PMID 29566106 DOI: 10.1001/jamaoncol.2018.0077 |
0.304 |
|
| 2018 |
Wagner J, Kline CL, Zhou L, Campbell KS, MacFarlane AW, Olszanski AJ, Cai KQ, Hensley HH, Ross EA, Ralff MD, Zloza A, Chesson CB, Newman JH, Kaufman H, Bertino JR, et al. Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment. The Journal of Clinical Investigation. PMID 29533922 DOI: 10.1172/Jci96711 |
0.397 |
|
| 2018 |
Kaufman HL, Russell JS, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbé C, Milella M, Brownell I, Lewis KD, Lorch JH, von Heydebreck A, Hennessy M, Nghiem P. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. Journal For Immunotherapy of Cancer. 6: 7. PMID 29347993 DOI: 10.1186/s40425-017-0310-x |
0.318 |
|
| 2018 |
Dorff TB, Wong MKK, Clark J, Daniels GA, Curti BD, Morse M, Kaufman H, McDermott DF, Quinn DI, Zang P, Gregory NC, Eifler LM, Thomas S, White M, Singh J, et al. High dose interleukin-2 and response in 944 patients with metastatic renal cell cancer (RCC): Data from the PROCLAIM registry. Journal of Clinical Oncology. 36: 624-624. DOI: 10.1200/Jco.2018.36.6_Suppl.624 |
0.363 |
|
| 2018 |
Silk AW, LeBoeuf NR, Rabinowits G, Puzanov I, Burgess MA, Devata S, Moore D, Goydos JS, Chen HX, Kaufman H, Zloza A, Mehnert JM. A phase II study of talimogene laherparepvec followed by talimogene laherparepvec + nivolumab in refractory T cell and NK cell lymphomas, cutaneous squamous cell carcinoma, Merkel cell carcinoma, and other rare skin tumors (NCI #10057). Journal of Clinical Oncology. 36: TPS219-TPS219. DOI: 10.1200/Jco.2018.36.5_Suppl.Tps219 |
0.465 |
|
| 2018 |
Fishman MN, Clark JI, Alva AS, Curti BD, Agarwal N, Hauke RJ, Mahoney KM, Moon H, Treisman J, Tykodi S, Daniels GA, Morse M, Wong MKK, Kaufman H, Gregory NC, et al. Overall survival (OS) by clinical risk category for high dose interleukin-2 (HD IL-2) treated metastatic renal cell cancer (RCC): Data from PROCLAIM. Journal of Clinical Oncology. 36: 4578-4578. DOI: 10.1200/Jco.2018.36.15_Suppl.4578 |
0.365 |
|
| 2017 |
Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM, Glaspy J, Hamid O, Ross M, Friedlander P, Garbe C, Logan TF, Hauschild A, Lebbé C, Chen L, Kim JJ, ... ... Kaufman HL, et al. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017737379. PMID 28981385 DOI: 10.1200/JCO.2017.73.7379 |
0.316 |
|
| 2017 |
Everett AS, Pavlidakey PG, Contreras CM, De Los Santos JF, Kim JY, McKee SB, Kaufman HL, Conry RM. Chronic Granulomatous Dermatitis Induced by Talimogene Laherparepvec Therapy of Melanoma Metastases. Journal of Cutaneous Pathology. PMID 28940544 DOI: 10.1111/cup.13048 |
0.318 |
|
| 2017 |
Bharmal M, Fofana F, Mahnke L, Schlichting M, Kaufman H. Non-progression during avelumab treatment is associated with clinically relevant improvements in health-related quality of life in patients with Merkel cell carcinoma. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E21070 |
0.353 |
|
| 2017 |
Kaufman H, Lambert J, Barbosa CD, Guillemin I, Mahnke L, Bharmal M. Patient experiences with avelumab vs chemotherapy for treating merkel cell carcinoma: Results from protocol-specified qualitative research. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E21065 |
0.377 |
|
| 2017 |
Clark J, Curti BD, Davis EJ, Kaufman H, Amin A, Alva AS, Johnson DB, White RL, Wiernik PH, Dutcher JP. Long-term (LT) disease-free survival (DFS) of melanoma (MM) and renal cell cancer (RCC) patients following high-dose interleukin-2 (HD IL2). Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E21005 |
0.391 |
|
| 2017 |
Kaufman H, Schwartz LH, William WN, Sznol M, del Aguila M, Whittington C, Fahrbach K, Xu Y, Masson E, Dempster S, Vergara-Silva AL. Evaluation of clinical endpoints as surrogates for overall survival in patients treated with immunotherapies. Journal of Clinical Oncology. 35: e14557-e14557. DOI: 10.1200/Jco.2017.35.15_Suppl.E14557 |
0.381 |
|
| 2017 |
Shapiro I, Grote HJ, D'Urso V, Heydebreck Av, Mahnke L, Kaufman H, Nghiem P, Cai T. Exploratory biomarker analysis in avelumab-treated patients with metastatic Merkel cell carcinoma progressed after chemotherapy. Journal of Clinical Oncology. 35: 9557-9557. DOI: 10.1200/Jco.2017.35.15_Suppl.9557 |
0.379 |
|
| 2017 |
D'Angelo SP, Russell J, Hassel JC, Lebbe C, Chmielowski B, Rabinowits G, Terheyden P, Brownell I, Zwiener I, Bajars M, Hennessy M, Kaufman H. First-line (1L) avelumab treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Preliminary data from an ongoing study. Journal of Clinical Oncology. 35: 9530-9530. DOI: 10.1200/Jco.2017.35.15_Suppl.9530 |
0.395 |
|
| 2017 |
Curti BD, Daniels GA, McDermott DF, Clark J, Kaufman H, Singh J, Kaur M, Luna TL, Gregory NC, Hua H, Morse M, Wong MKK, Dutcher JP. Association of improved survival (OS) and tumor control (TC) with interleukin-2 (IL2) with development of immune-related events (IREs): Data from the PROCLAIMSM registry. Journal of Clinical Oncology. 35: 9528-9528. DOI: 10.1200/Jco.2017.35.15_Suppl.9528 |
0.361 |
|
| 2017 |
Rodriguez-Rodriguez L, Mehnert JM, Silk AW, Chan N, Malhotra J, Aisner J, Saunders T, Yu B, Dickerson S, Tarapore R, Allen JE, Stogniew M, Oster W, Kaufman H, Haffty BG, et al. Clinical activity of the selective DRD2 antagonist ONC201, an imipridone, in metastatic endometrial cancer (mEC). Journal of Clinical Oncology. 35: 5592-5592. DOI: 10.1200/Jco.2017.35.15_Suppl.5592 |
0.41 |
|
| 2017 |
Stein MN, Chan N, Silk AW, Malhotra J, Aisner J, Aiken R, Zloza A, El-Deiry WS, Newman J, Chesson C, Tarapore R, Allen JE, Oster W, Saunders T, Yu B, ... ... Kaufman H, et al. Anticancer and immunostimulatory activity of the imipridone ONC201, a selective DRD2 antagonist, in advanced cancer patients. Journal of Clinical Oncology. 35: 2586-2586. DOI: 10.1200/Jco.2017.35.15_Suppl.2586 |
0.406 |
|
| 2017 |
Silk AW, Kaufman H, Gabrail N, Mehnert J, Bryan J, Norrell J, Medina D, Bommareddy P, Shafren D, Grose M, Zloza A. Abstract CT026: Phase 1b study of intratumoral Coxsackievirus A21 (CVA21) and systemicpembrolizumab inadvanced melanoma patients: Interim results of the CAPRA clinical trial Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct026 |
0.483 |
|
| 2017 |
Wagner J, Kline CL, Zhou L, Zloza A, Chesson C, Newman J, Kaufman H, Bertino J, Stein M, El-Deiry W. Abstract 124: Imipridone ONC201 promotes intra-tumoral accumulation of CD3+/NK+ cells that contribute to its anti-tumor efficacy Cancer Research. 77: 124-124. DOI: 10.1158/1538-7445.Am2017-124 |
0.378 |
|
| 2017 |
Kaufman H, Hunger M, Hennessy M, Schlichting M, Bharmal M. Minimal Impact on Patients’ Health Utilities Associated with Adverse Events in Metastatic Merkel Cell Carcinoma Patients on Treatment with Avelumab Value in Health. 20. DOI: 10.1016/J.Jval.2017.08.281 |
0.308 |
|
| 2017 |
Jerusalem G, Chen F, Spigel D, Iannotti N, Mcclay E, Redfern C, Bennouna J, Taylor M, Kaufman H, Kelly K, Chand V, Heydebreck AV, Verschraegen C. OA03.03 JAVELIN Solid Tumor: Safety and Clinical Activity of Avelumab (Anti-PD-L1) as First-Line Treatment in Patients with Advanced NSCLC Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.240 |
0.353 |
|
| 2016 |
Bommareddy PK, Patel A, Hossain S, Kaufman HL. Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma. American Journal of Clinical Dermatology. PMID 27988837 DOI: 10.1007/s40257-016-0238-9 |
0.301 |
|
| 2016 |
Alva A, Daniels GA, Wong MK, Kaufman HL, Morse MA, McDermott DF, Clark JI, Agarwala SS, Miletello G, Logan TF, Hauke RJ, Curti B, Kirkwood JM, Gonzalez R, Amin A, et al. Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunology, Immunotherapy : Cii. PMID 27714434 DOI: 10.1007/s00262-016-1910-x |
0.318 |
|
| 2016 |
Wong MKK, Morse M, McDermott DF, Clark J, Kaufman H, Daniels GA, Dutcher JP, Perritt JC, Hua H, Rao T. Update on the overall survival of patients with metastatic melanoma treated with immune checkpoint blockade following initial treatment with HD IL-2. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E21039 |
0.412 |
|
| 2016 |
Buchbinder EI, Dutcher JP, Perritt JC, Clark J, Holtan SG, Kirkwood JM, Curti BD, Lao CD, Kaufman H, Fishman MN, McDermott DF. A Prospective Analysis of High-Dose Interleukin-2 (HD IL-2) following PD-1 inhibitor therapy in patients with metastatic melanoma and renal cell carcinoma. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E21006 |
0.397 |
|
| 2016 |
Andtbacka RHI, Curti BD, Kaufman H, Nemunaitis JJ, Daniels GA, Hallmeyer S, Whitman ED, Lutzky J, Schultz SM, Spitler LE, Feng Z, Paustian C, Fox BA, Bifulco CB, Zhou K, et al. Dynamics of tumor response in advanced melanoma patients treated with Coxsackievirus A21. Journal of Clinical Oncology. 34: 9553-9553. DOI: 10.1200/Jco.2016.34.15_Suppl.9553 |
0.338 |
|
| 2016 |
Kaufman H, Russell JS, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbe C, Linette GP, Milella M, Brownell I, Lewis KD, Lorch JH, Chin KM, Mahnke L, et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic Merkel cell carcinoma previously treated with chemotherapy: Results of the phase 2 JAVELIN Merkel 200 trial. Journal of Clinical Oncology. 34: 9508-9508. DOI: 10.1200/Jco.2016.34.15_Suppl.9508 |
0.439 |
|
| 2016 |
Verschraegen CF, Chen F, Spigel DR, Iannotti N, McClay EF, Redfern CH, Bennouna J, Taylor MH, Kaufman H, Kelly K, Bajars M, Heydebreck Av, Cuillerot J, Jerusalem GHM. Avelumab (MSB0010718C ; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN Solid Tumor phase 1b trial : safety, clinical activity, and PD-L1 expression Journal of Clinical Oncology. 34: 9036-9036. DOI: 10.1200/Jco.2016.34.15_Suppl.9036 |
0.383 |
|
| 2016 |
Clark J, McDermott DF, Dutcher JP, Wong MKK, Kaufman H, Daniels GA, Morse M, Perritt JC, Hua H, Rao T. Extension of overall survival in patients with metastatic renal cell carcinoma who received HD IL-2 followed by targeted therapy and/or immune checkpoint blockade from the PROCLAIM registry. Journal of Clinical Oncology. 34: 4548-4548. DOI: 10.1200/Jco.2016.34.15_Suppl.4548 |
0.369 |
|
| 2016 |
Kelly K, Heery CR, Patel MR, Infante JR, Iannotti N, Leach JW, Wang D, Chandler JC, Arkenau H, Taylor MH, Gordon MS, Wong DJL, Safran H, Kaufman H, Keilholz U, et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced cancer: Safety data from 1300 patients enrolled in the phase 1b JAVELIN Solid Tumor trial. Journal of Clinical Oncology. 34: 3055-3055. DOI: 10.1200/Jco.2016.34.15_Suppl.3055 |
0.418 |
|
| 2016 |
Stein MN, Chan N, Silk AW, Fang B, Kaufman H, Haffty BG, Saunders T, Najmi S, Zheng L, Stogniew M, Allen JE, Oster W, Bertino JR, Mehnert JM. First-in-human trial of ONC201 in patients with refractory solid tumors. Journal of Clinical Oncology. 34: 2514-2514. DOI: 10.1200/Jco.2016.34.15_Suppl.2514 |
0.379 |
|
| 2016 |
Kaufman H, Kraemer M, Barbosa CD, Lambert J, Mahnke L, Bharmal M. Patient Perspectives on Merkel Cell Carcinoma (MCC) and Its Treatment with A Novel Agent (AVELUMAB): Findings From In-Depth Qualitative Patient Interviews Value in Health. 19. DOI: 10.1016/J.Jval.2016.09.2281 |
0.337 |
|
| 2015 |
Harrington KJ, Puzanov I, Hecht JR, Hodi FS, Szabo Z, Murugappan S, Kaufman HL. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy. Expert Review of Anticancer Therapy. 15: 1389-403. PMID 26558498 DOI: 10.1586/14737140.2015.1115725 |
0.315 |
|
| 2015 |
Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K, Ross M, et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26014293 DOI: 10.1200/Jco.2014.58.3377 |
0.307 |
|
| 2015 |
Kohlhapp FJ, Broucek JR, Hughes T, Huelsmann EJ, Lusciks J, Zayas JP, Dolubizno H, Fleetwood VA, Grin A, Hill GE, Poshepny JL, Nabatiyan A, Ruby CE, Snook JD, Rudra JS, ... ... Kaufman HL, et al. NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade. Journal For Immunotherapy of Cancer. 3: 18. PMID 25992289 DOI: 10.1186/S40425-015-0063-3 |
0.307 |
|
| 2015 |
Dharmadhikari N, Mehnert JM, Kaufman HL. Oncolytic virus immunotherapy for melanoma. Current Treatment Options in Oncology. 16: 326. PMID 25777572 DOI: 10.1007/s11864-014-0326-0 |
0.338 |
|
| 2015 |
Hughes T, Klairmont M, Broucek J, Iodice G, Basu S, Kaufman HL. The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunology, Immunotherapy : Cii. 64: 459-65. PMID 25603775 DOI: 10.1007/S00262-014-1652-6 |
0.325 |
|
| 2015 |
Clark J, Wong M, Daniels G, Kaufman H, McDermott D, Morse M, Aung S. Stable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2 F1000research. 6. DOI: 10.7490/F1000Research.1097402.1 |
0.316 |
|
| 2015 |
Aung S, Morse MA, Wong MK, Kaufman H, Daniels GA, McDermott DF. High dose (HD) IL-2 for metastatic renal cell carcinoma (mRCC) in the targeted therapy era: Extension of OS benefits beyond complete response (CR) and partial response (PR). Journal of Clinical Oncology. 33: 423-423. DOI: 10.1200/Jco.2015.33.7_Suppl.423 |
0.403 |
|
| 2015 |
Spencer KR, Kaveney AD, Goydos J, Kim S, Koshenkov VP, Goyal S, Khan AJ, Castrorao EM, Silk AW, Kaufman H, Huzzy L, Ruppert ML, Ganesan S, Mehnert JM. A pilot study of neoadjuvant cetuximab in locally advanced squamous cell carcinomas of skin (SCCS). Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.Tps9092 |
0.393 |
|
| 2015 |
Kaufman H, Hamid O, D'Angelo SP, Yuan G, Chin KM, Bhatia S, Cuillerot J, Nghiem P. A phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab (MSB0010718C) in patients with metastatic Merkel cell carcinoma. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.Tps9086 |
0.414 |
|
| 2015 |
Kaufman H, Wang J, Curti BD, Clark J, Ernstoff MS, Silk A, Mehnert JM, Zloza A, Shih J, McDermott DF. A Phase II multicenter trial to evaluate combination ipilimumab and high-dose IL-2 in patients with unresectable stage III and IV melanoma. Journal of Clinical Oncology. 33: TPS3095-TPS3095. DOI: 10.1200/Jco.2015.33.15_Suppl.Tps3095 |
0.418 |
|
| 2015 |
Wong MKK, Morse M, McDermott DF, Clark J, Kaufman H, Daniels GA, Hua H, Aung S. Overall survival of metastatic melanoma (mM) treated with high dose IL-2 (HD IL-2) followed by anti-CTLA4 (IPI) and/or anti-PD-1/PDL1 (aPD1) therapy: Analysis of the prospective cohort of the PROCLAIM national registry. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E20071 |
0.345 |
|
| 2015 |
Clark J, Morse M, Wong MKK, McDermott DF, Kaufman H, Daniels GA, Hua H, Aung S. Impact of targeted therapy (TT) on survival of metastatic renal cell carcinoma (mRCC) patients treated with high dose interleukin-2 (HD IL-2): Analysis of the PROCLAIM HD IL-2 National Registry. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E15609 |
0.384 |
|
| 2015 |
Kaufman H, Amatruda T, Nemunaitis JJ, Chesney JA, Delman KA, Spitler LE, Collichio FA, Ross MI, Zhang Y, Shilkrut M, Andtbacka RHI. Tumor size and clinical outcomes in melanoma patients (MEL pts) treated with talimogene laherparepvec (T-VEC). Journal of Clinical Oncology. 33: 9074-9074. DOI: 10.1200/Jco.2015.33.15_Suppl.9074 |
0.414 |
|
| 2015 |
Puzanov I, Milhem MM, Andtbacka RHI, Minor DR, Hamid O, Li A, Chou J, Kaufman H. Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. Journal of Clinical Oncology. 33: 9063-9063. DOI: 10.1200/Jco.2015.33.15_Suppl.9063 |
0.383 |
|
| 2015 |
Andtbacka RHI, Curti BD, Kaufman H, Daniels GA, Nemunaitis JJ, Spitler LE, Hallmeyer S, Lutzky J, Schultz SM, Whitman ED, Zhou K, Karpathy R, Weisberg JI, Grose M, Shafren D. Final data from CALM: A phase II study of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma. Journal of Clinical Oncology. 33: 9030-9030. DOI: 10.1200/Jco.2015.33.15_Suppl.9030 |
0.441 |
|
| 2015 |
Johnson DB, Khushalani NI, Puzanov I, Mudigonda T, Kaufman H, Sosman JA, Mehnert JM, Clark J. Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. Journal of Clinical Oncology. 33: 9019-9019. DOI: 10.1200/Jco.2015.33.15_Suppl.9019 |
0.379 |
|
| 2015 |
Kohlhapp F, Huelsmann E, Broucek J, Schenkel J, Kaufman H, Zloza A. Acute viral infection results in a PD-1-dependent loss of anti-tumor CD8+ T cell responses: implications for tumor immunotherapy Journal For Immunotherapy of Cancer. 3: P281. DOI: 10.1186/2051-1426-3-S2-P281 |
0.35 |
|
| 2015 |
Andtbacka RHI, Kaufman H, Collichio F, Amatruda T, Nemunaitis J, Chesney J, Puzanov I, Harrington K, Zhang Y, Chen L, Shilkrut M, Ross M. 3334 Durable complete responses (CR) in patients (pts) with stage IIIB-IV melanoma treated with talimogene laherparepvec (T-VEC) in OPTiM European Journal of Cancer. 51. DOI: 10.1016/S0959-8049(16)31852-4 |
0.346 |
|
| 2014 |
Collichio FA, Milhem M, Andtbacka RH, Puzanov I, Saenger Y, Chesney J, Cranmer L, Hamid O, Logan T, Glaspy J, Lebbé C, Garbe C, Gansert J, Li A, Chou J, ... Kaufman H, et al. 1129TiPA PHASE 1B/2, MULTICENTER, OPEN LABEL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF TALIMOGENE LAHERPAREPVEC (T-VEC) AND IPILIMUMAB (IPI) VERSUS IPI ALONE IN PREVIOUSLY UNTREATED, UNRESECTED, STAGE IIIB, IIIC, AND IV MELANOMA. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv391-iv392. PMID 28171214 DOI: 10.1093/Annonc/Mdu344.45 |
0.426 |
|
| 2014 |
Nemunaitis JJ, Andtbacka RH, Ross M, Amatruda T, Chesney J, Collichio FA, Harrington KJ, Steven NM, Fourie S, Dreosti L, Li A, Liu K, Shilkrut M, Coffin R, Kaufman H. 1102PRESULTS OF THE EXTENSION TRIAL OF OPTIM, A MULTICENTER, RANDOMIZED PHASE 3 TRIAL OF TALIMOGENE LAHERPAREPVEC (T-VEC) VS GM-CSF FOR UNRESECTED STAGE IIIB-IV MELANOMA. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv382. PMID 28171147 DOI: 10.1093/Annonc/Mdu344.18 |
0.37 |
|
| 2014 |
Andtbacka RH, Curti B, Kaufman H, Daniels GA, Nemunaitis JJ, Spitler LE, Hallmeyer S, Lutzky J, Schultz S, Whitman ED, Zhou K, Weisberg JI, Shafren D. 1103PCALM STUDY: SECONDARY ENDPOINTS OF A PHASE II STUDY OF A NOVEL ONCOLYTIC IMMUNOTHERAPEUTIC AGENT, COXSACKIEVIRUS A21, DELIVERED INTRATUMORALLY IN PATIENTS WITH ADVANCED MALIGNANT MELANOMA. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv382. PMID 28171124 DOI: 10.1093/Annonc/Mdu344.19 |
0.442 |
|
| 2014 |
Hughes T, Coffin RS, Lilley CE, Ponce R, Kaufman HL. Critical analysis of an oncolytic herpesvirus encoding granulocyte-macrophage colony stimulating factor for the treatment of malignant melanoma. Oncolytic Virotherapy. 3: 11-20. PMID 27512660 DOI: 10.2147/OV.S36701 |
0.305 |
|
| 2014 |
Kaufman HL, Ruby CE, Hughes T, Slingluff CL. Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. Journal For Immunotherapy of Cancer. 2: 11. PMID 24971166 DOI: 10.1186/2051-1426-2-11 |
0.301 |
|
| 2014 |
Kaufman HL, Kim DW, Kim-Schulze S, DeRaffele G, Jagoda MC, Broucek JR, Zloza A. Results of a randomized phase I gene therapy clinical trial of nononcolytic fowlpox viruses encoding T cell costimulatory molecules. Human Gene Therapy. 25: 452-60. PMID 24484178 DOI: 10.1089/hum.2013.217 |
0.333 |
|
| 2014 |
Lowder JN, Aung S, Wong MKK, Daniels GA, Kaufman H, McDermott DF, Morse M. High-dose interleukin-2 registry, PROCLAIM: Modern data on toxicities and outcomes. Journal of Clinical Oncology. 32: 430-430. DOI: 10.1200/Jco.2014.32.4_Suppl.430 |
0.379 |
|
| 2014 |
Daniels GA, Morse M, Wong MKK, Kaufman H, McDermott DF, Aung S, Lowder JN. Improved median overall survival (OS) in patients with metastatic melanoma (mM) treated with high-dose (HD) IL-2: Analysis of the PROCLAIM 2007-2012 national registry. Journal of Clinical Oncology. 32: 9054-9054. DOI: 10.1200/Jco.2014.32.15_Suppl.9054 |
0.375 |
|
| 2014 |
Puzanov I, Milhem MM, Andtbacka RHI, Minor DR, Hamid O, Li A, Chastain M, Gorski K, Anderson A, Vanderwalde AM, Chou J, Kaufman H. Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. Journal of Clinical Oncology. 32: 9029-9029. DOI: 10.1200/Jco.2014.32.15_Suppl.9029 |
0.385 |
|
| 2014 |
Andtbacka RHI, Curti BD, Kaufman H, Daniels GA, Nemunaitis JJ, Spitler LE, Hallmeyer S, Lutzky J, Schultz S, Whitman ED, Zhou K, Weisberg JI, Shafren D. CALM study: A phase II study of an intratumorally delivered oncolytic immunotherapeutic agent, coxsackievirus A21, in patients with stage IIIc and stage IV malignant melanoma. Journal of Clinical Oncology. 32: 3031-3031. DOI: 10.1200/Jco.2014.32.15_Suppl.3031 |
0.316 |
|
| 2014 |
Broucek J, Hughes T, Huelsmann E, Lusciks E, Hill G, Zayas J, Poshepny J, Ruby C, Kohlhapp F, Zloza A, Kaufman H. Combination immunotherapy with anti-CTLA-4 and interleukin-2 redirects regulatory T cells into tumor-draining lymph nodes and expands anti-tumor CD8+ T cells in the tumor microenvironment Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P97 |
0.376 |
|
| 2014 |
Andtbacka RH, Collichio FA, Amatruda T, Senzer N, Chesney J, Delman K, Spitler L, Puzanov I, Agarwala S, Milhem M, Harrington K, Middleton M, Li A, Shilkrut M, Coffin R, ... Kaufman H, et al. Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704) Journal For Immunotherapy of Cancer. 2: 263. DOI: 10.1186/2051-1426-2-S3-P263 |
0.389 |
|
| 2014 |
Sarantopoulos J, Goel S, Chung V, Munster P, Pant S, Patel M, Infante J, Tawbi H, Becerra C, Bruce J, Kabbinavar F, Kaufman H, Lockhart AC, Tan E, Yang S, et al. Abstract 4640: Randomized, phase 1 crossover study assessing the bioequivalence of tablet and capsule formulations of dovitinib (TKI258) Cancer Research. 74: 4640-4640. DOI: 10.1158/1538-7445.Am2014-4640 |
0.364 |
|
| 2013 |
Andtbacka RHI, Kaufman H, Daniels GA, Spitler LE, Lutzky J, Hallmeyer S, Whitman ED, Nemunaitis JJ, Zhou K, Karpathy R, Weisberg JI, Shafren D. CALM study: A phase II study of intratumoral coxsackievirus A21 in patients with stage IIIc and stage IV malignant melanoma. Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps3128 |
0.328 |
|
| 2013 |
Sosman JA, Martin-Algarra S, Wolchok JD, Sharfman WH, Bhatia S, Hodi FS, Hwu W, Gajewski T, Slingluff CL, Kaufman H, Gupta M, McGirr A, Horak CE, Ahlers CM, Wigginton JM, et al. An exploratory study of the biologic effects of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) treatment in patients (pts) with advanced (unresectable or metastatic) melanoma (MEL). Journal of Clinical Oncology. 31: TPS3114-TPS3114. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps3114 |
0.44 |
|
| 2013 |
Andtbacka RHI, Collichio FA, Amatruda T, Senzer NN, Chesney J, Delman KA, Spitler LE, Puzanov I, Doleman S, Ye Y, Vanderwalde AM, Coffin R, Kaufman H. OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. Journal of Clinical Oncology. 31: LBA9008-LBA9008. DOI: 10.1200/Jco.2013.31.15_Suppl.Lba9008 |
0.321 |
|
| 2013 |
Kaufman H, Lutzky J, Clark J, Margolin KA, Lawson DH, Amin A, Collichio FA, Pecora A, Urba WJ, Bennett KL, McDermott DF. Safety and efficacy of ipilimumab in melanoma patients who received prior immunotherapy on phase III study MDX010-020. Journal of Clinical Oncology. 31: 9050-9050. DOI: 10.1200/Jco.2013.31.15_Suppl.9050 |
0.382 |
|
| 2013 |
Puzanov I, Milhem M, Andtbacka R, Minor D, Hamid O, Li A, VanderWalde A, Kaufman H. Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously untreated, unresected stage IIIB-IV melanoma Journal For Immunotherapy of Cancer. 1: 84. DOI: 10.1186/2051-1426-1-S1-P84 |
0.403 |
|
| 2013 |
Stonewall K, Quintero C, Zloza A, Kaufman H, Ruby C. The impact of age on a mitoxantrone-based tumor vaccine Journal For Immunotherapy of Cancer. 1: P234. DOI: 10.1186/2051-1426-1-S1-P234 |
0.366 |
|
| 2013 |
Hughes T, Iodice GM, Basu S, Bines S, Kaufman H. The role of surgery following incomplete response to high-dose IL-2 (HD IL-2) Journal For Immunotherapy of Cancer. 1: 145. DOI: 10.1186/2051-1426-1-S1-P145 |
0.41 |
|
| 2013 |
Hughes T, Iodice GM, Basu S, Bines S, Kaufman H. Clinical benefit of high dose IL-2 (HD IL-2) therapy: evidence for improved overall survival in patients with stable disease Journal For Immunotherapy of Cancer. 1: 105. DOI: 10.1186/2051-1426-1-S1-P105 |
0.403 |
|
| 2012 |
Berinstein NL, Karkada M, Morse MA, Nemunaitis JJ, Chatta G, Kaufman H, Odunsi K, Nigam R, Sammatur L, MacDonald LD, Weir GM, Stanford MM, Mansour M. First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. Journal of Translational Medicine. 10: 156. PMID 22862954 DOI: 10.1186/1479-5876-10-156 |
0.316 |
|
| 2012 |
Zhang RT, Bines SD, Ruby C, Kaufman HL. TroVax(®) vaccine therapy for renal cell carcinoma. Immunotherapy. 4: 27-42. PMID 22149999 DOI: 10.2217/imt.11.160 |
0.316 |
|
| 2012 |
Lazarus M, Kaufman H. An association between corticosteroid use and melanoma recurrence: a case report and review of the literature. Medical Oncology (Northwood, London, England). 29: 2018-20. PMID 21922297 DOI: 10.1007/S12032-011-0064-0 |
0.347 |
|
| 2012 |
Kaufman H, Wagner VJ, Goldsweig H, Yao B, Coffin R. OPTiM: A randomized phase III trial to evaluate the efficacy and safety of talimogene laherparepvec (T-VEC) compared with subcutaneously (sc) administered GM-CSF for the treatment (tx) of unresectable stage IIIb, IIIc, and IV melanoma. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.Tps8604 |
0.384 |
|
| 2012 |
Berinstein NL, Karkada M, Nigam R, Morse M, Nemunaitis JJ, Chatta GS, Kaufman H, Odunsi K, Weir G, MacDonald L, Stanford M, Mansour M. Effect of the novel therapeutic cancer vaccine formulation DPX-0907 on multifunctional T-cell responses in ovarian, breast, and prostate cancer patients. Journal of Clinical Oncology. 30: 2588-2588. DOI: 10.1200/Jco.2012.30.15_Suppl.2588 |
0.391 |
|
| 2011 |
Harrop R, Shingler WH, McDonald M, Treasure P, Amato RJ, Hawkins RE, Kaufman H, de Belin J, Goonewardena M, Naylor S. Identification of pre- and post-treatment markers of efficacy in patients with renal cancer treated with MVA-5T4 in a phase III study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2542. PMID 28022317 DOI: 10.1200/Jco.2011.29.15_Suppl.2542 |
0.369 |
|
| 2011 |
Berinstein NL, Morse M, Kaufman H, Nemunaitis JJ, Odunsi K, Chatta GS, Weir G, MacDonald L, Stanford M, Karkada M, Nigam R, Mansour M. A phase I study of the safety and immunogenicity of a therapeutic vaccine, DPX-0907 in patients with advanced-stage ovarian, breast, or prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e13050. PMID 28019867 DOI: 10.1200/Jco.2011.29.15_Suppl.E13050 |
0.327 |
|
| 2011 |
Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, Kendra KL, White RL, Gonzalez R, Kuzel TM, Curti B, ... ... Kaufman H, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. The New England Journal of Medicine. 364: 2119-27. PMID 21631324 DOI: 10.1056/Nejmoa1012863 |
0.36 |
|
| 2011 |
Harrop R, Shingler WH, McDonald M, Treasure P, Amato RJ, Hawkins RE, Kaufman HL, de Belin J, Kelleher M, Goonewardena M, Naylor S. MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients. Cancer Immunology, Immunotherapy : Cii. 60: 829-37. PMID 21387109 DOI: 10.1007/s00262-011-0993-7 |
0.324 |
|
| 2010 |
Kim D, Kim-Schulze S, Deraffele G, Schlom J, Kaufman H. Evaluation of poxviruses targeting the tumor microenvironment for cancer therapy. Journal of Clinical Oncology. 28: 2600-2600. DOI: 10.1200/Jco.2010.28.15_Suppl.2600 |
0.39 |
|
| 2009 |
Senzer NN, Kaufman H, Amatruda T, Nemunaitis M, Daniels G, Glaspy J, Goldsweig H, Coffin RS, Nemunaitis J. Phase II clinical trial with a second generation, GM-CSF encoding, oncolytic herpesvirus in unresectable metastatic melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 9035. PMID 27962090 DOI: 10.1200/Jco.2009.27.15_Suppl.9035 |
0.345 |
|
| 2009 |
Kaufman HL, Taback B, Sherman W, Kim DW, Shingler WH, Moroziewicz D, DeRaffele G, Mitcham J, Carroll MW, Harrop R, Naylor S, Kim-Schulze S. Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. Journal of Translational Medicine. 7: 2. PMID 19128501 DOI: 10.1186/1479-5876-7-2 |
0.32 |
|
| 2007 |
Suciu-Foca N, Feirt N, Zhang QY, Vlad G, Liu Z, Lin H, Chang CC, Ho EK, Colovai AI, Kaufman H, D'Agati VD, Thaker H, Remotti H, Galluzzo S, Cinti P, et al. Soluble Ig-Like Transcript 3 Inhibits Tumor Allograft Rejection in Humanized SCID Mice and T Cell Responses in Cancer Patients Journal of Immunology. 178: 7432-7441. PMID 17513794 DOI: 10.4049/Jimmunol.178.11.7432 |
0.391 |
|
| 2007 |
Cesana GC, Romano F, Piacentini G, Scotti M, Brenna A, Bovo G, Vaghi M, Aletti G, Caprotti R, Kaufman H, Uggeri F. Low-dose interleukin-2 administered pre-operatively to patients with gastric cancer activates peripheral and peritumoral lymphocytes but does not affect prognosis. Annals of Surgical Oncology. 14: 1295-304. PMID 17225981 DOI: 10.1245/S10434-006-9239-X |
0.36 |
|
| 2006 |
Kaufman HL, Wolchok JD. Is Tumor Immunity the Same Thing As Autoimmunity? Implications for Cancer Immunotherapy Journal of Clinical Oncology. 24: 2230-2232. PMID 16710020 DOI: 10.1200/Jco.2006.05.6952 |
0.32 |
|
| 2006 |
Kaufman HL, Cohen S, Cheung K, DeRaffele G, Mitcham J, Moroziewicz D, Schlom J, Hesdorffer C. Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors. Human Gene Therapy. 17: 239-44. PMID 16454657 DOI: 10.1089/hum.2006.17.239 |
0.332 |
|
| 2006 |
Manson K, Dolan KE, Marshall J, Kaufman H, Mazzara GP, Schuetz TJ. A novel non-HLA-restricted cellular immune assay for monitoring patient (pt) response to targeted immunotherapeutics Journal of Clinical Oncology. 24: 2567-2567. DOI: 10.1200/Jco.2006.24.18_Suppl.2567 |
0.368 |
|
| 2006 |
Ugurel S, Schrama D, Gunhild K, Zapatka M, Fink W, Kaufman H, Becker J. CCR5 gene polymorphism in patients with cutaneous melanoma: impact on survival following immunotherapy Melanoma Research. 16: S45. DOI: 10.1097/00008390-200609001-00079 |
0.309 |
|
| 2005 |
Kaufman HL, Deraffele G, Mitcham J, Moroziewicz D, Cohen SM, Hurst-Wicker KS, Cheung K, Lee DS, Divito J, Voulo M, Donovan J, Dolan K, Manson K, Panicali D, Wang E, et al. Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. The Journal of Clinical Investigation. 115: 1903-12. PMID 15937544 DOI: 10.1172/JCI24624 |
0.325 |
|
| 2004 |
Lochhead R, McKhann G, Hankinson T, Isaacson S, Hesdorffer C, DeRaffele G, Sisti J, Bruce J, Kaufman H. High Dose Systemic Interleukin-2 for Metastatic Melanoma in Patients with Treated Brain Metastases Journal of Immunotherapy. 27. DOI: 10.1097/00002371-200411000-00058 |
0.322 |
|
| 2000 |
Chamberlain RS, Kaufman H. Innovations and strategies for the development of anticancer vaccines Expert Opinion On Pharmacotherapy. 1: 603-614. PMID 11249505 DOI: 10.1517/14656566.1.4.603 |
0.307 |
|
| 1992 |
Kantor J, Irvine K, Abrams S, Kaufman H, Dipietro J, Schlom J. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine Journal of the National Cancer Institute. 84: 1084-1091. PMID 1619682 DOI: 10.1093/Jnci/84.14.1084 |
0.363 |
|
| 1991 |
Kaufman H, Schlom J, Kantor J. A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA) International Journal of Cancer. 48: 900-907. PMID 1860736 DOI: 10.1002/Ijc.2910480618 |
0.313 |
|
| Show low-probability matches. |